Conferences
ASCO GU 2024: Salvage Radiotherapy Options for Biochemical Recurrence After Local Treatment
January 26, 2024
ASCO GU 2024: A Phase 1/2 Study of ONCT-534, a Dual-Action Androgen Receptor Inhibitor in Patients with Metastatic Castration-Resistant Prostate Cancer
January 26, 2024
ASCO GU 2024: Disparities in Prostate Cancer Mortality and Clinical Trial Availability Across Vulnerable Populations
January 26, 2024
ASCO GU 2024: Differences in Genomic, Transcriptomic, and Immune Landscape of Prostate Cancer Based on Site of Metastasis
January 26, 2024
ASCO GU 2024: Phase 1b/2 Study of Pembrolizumab Plus Belzutifan and Belzutifan Alone in Patients with Docetaxel-treated mCRPC: KEYNOTE-365 Cohort J
January 26, 2024